Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335645 | 0.73 | ALOX5 (0.49) | PPARAPPARGKCNH2ALOX5PTGS2 | |
| SCHEMBL8939752 | 0.70 | ADRA1D (0.42) | — | |
| SCHEMBL20534622 | 0.70 | CSNK1E (0.37) | HTR2A | |
| SCHEMBL27823090 | 0.69 | LTA4H (0.41) | HTR2AKCNH2 | |
| SCHEMBL20534805 | 0.69 | CSNK1E (0.39) | THRATHRBHTR2ACYP19A1KCNH2 | |
| SCHEMBL12817362 | 0.69 | ALOX5 (0.42) | PPARAALOX5PTGS2 | |
| SCHEMBL6678195 | 0.68 | NPC1 (0.42) | HTR2AKCNH2 | |
| SCHEMBL6541323 | 0.68 | NPC1 (0.42) | HTR2AKCNH2 | |
| SCHEMBL6541581 | 0.68 | NPC1 (0.42) | HTR2AKCNH2 | |
| SCHEMBL28035354 | 0.68 | NPC1 (0.42) | HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703991-B2 | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703991-B2 | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120004442-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004442-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2365746-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | Wellstat Therapeutics Corporation (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2365746-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | Wellstat Therapeutics Corporation (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010053910-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053910-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004442-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | PGD, HPD, MLYCD | THRA 2536/4885THRB 2246/4885HTR2A 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.